Comparative Pharmacology
Head-to-head clinical analysis: EMTRICITABINE versus TENOFOVIR ALAFENAMIDE FUMARATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMTRICITABINE versus TENOFOVIR ALAFENAMIDE FUMARATE.
EMTRICITABINE vs TENOFOVIR ALAFENAMIDE FUMARATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nucleoside reverse transcriptase inhibitor; phosphorylated to emtricitabine triphosphate which competes with endogenous deoxycytidine triphosphate and incorporates into viral DNA causing chain termination.
Tenofovir alafenamide fumarate is a nucleotide reverse transcriptase inhibitor. It is a prodrug that is hydrolyzed intracellularly to tenofovir diphosphate, which inhibits HIV reverse transcriptase and hepatitis B virus polymerase by competing with the natural substrate deoxyadenosine 5'-triphosphate and by DNA chain termination after incorporation into viral DNA.
200 mg orally once daily, typically in combination with other antiretroviral agents.
25 mg orally once daily with food.
None Documented
None Documented
Clinical Note
moderateEmtricitabine + Ribavirin
"Emtricitabine may increase the hepatotoxic activities of Ribavirin."
Clinical Note
moderateLamivudine + Emtricitabine
"The risk or severity of adverse effects can be increased when Lamivudine is combined with Emtricitabine."
Clinical Note
moderateGanciclovir + Emtricitabine
"The risk or severity of adverse effects can be increased when Ganciclovir is combined with Emtricitabine."
Clinical Note
moderateValganciclovir + Emtricitabine
Terminal elimination half-life is approximately 10 hours (range 8–12 hours) in adults with normal renal function; prolonged to >20 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is approximately 0.51 hours (range 0.37-0.77 hours) for tenofovir alafenamide, while the active metabolite tenofovir diphosphate has a prolonged intracellular half-life of approximately 150-180 hours in PBMCs, supporting once-daily dosing.
Renal: approximately 86% of the dose is excreted unchanged in urine via glomerular filtration and active tubular secretion. Biliary/fecal: minimal (<14% as unchanged drug and metabolites in feces).
Following oral administration, approximately 32% of the tenofovir alafenamide dose is excreted unchanged in urine via active tubular secretion and glomerular filtration; the remainder is eliminated as metabolites, primarily through fecal excretion (approximately 47%) and minor biliary elimination, with less than 1% excreted unchanged in feces.
Category C
Category A/B
Antiretroviral, NRTI
NRTI
"The risk or severity of adverse effects can be increased when Valganciclovir is combined with Emtricitabine."